Keyword: Sun Pharma Advanced Research Company (SPARC)
After years of criticism from the FDA, Sun’s Halol plant still can’t get through an FDA inspection without the agency finding some deficiency.
India’s Sun Pharmaceuticals, which is working to shift its focus to novel and specialty drugs, has won FDA approval of a new treatment for glaucoma.
After more than two years of intense effort, Sun Pharma has returned its key plant to the good graces of the FDA.
The manufacturing problems at Sun Pharma’s key Halol, India, plant have again stymied approval of a new drug from Sun's novel drug development group, SPARC.